Key facts
- Woodline Partners LP filed SCHEDULE 13G for OKYO Pharma LTD Ordinary Shares, no par value (OKYO).
- Disclosed ownership: 7%.
- Date of event: 31 Mar 2026.
Woodline Partners LP - 31 Mar 2026 SCHEDULE 13G Report for OKYO Pharma LTD Ordinary Shares, no par value (OKYO)
- Filing Manager
- Woodline Partners LP
- Reporting Manager
- Woodline Partners LP
- Symbol
- OKYO
- Shares outstanding
- 52,174,143 shares
- Disclosed Ownership
- 3,652,190 shares
- Ownership
- 7%
- Form type
- SCHEDULE 13G
- Filing time
- 15 May 2026, 09:01:27 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Key filing fact
Woodline Partners LP disclosed 7% ownership in OKYO Pharma LTD Ordinary Shares, no par value (OKYO) on 31 Mar 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2026, 09:01.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Woodline Partners LP | 7% | 3,652,190 | 3,652,190 | 0 | /s/ Erin Mullen | Erin Mullen, General Counsel & Chief Compliance Officer |
CIK / CUSIP context first